Metabolic disorder
Methodology & AI Transparency ⓘ
Metabolic disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Metabolic disorder—coded clinically as E88.9 across Weight & Metabolism guidelines—combines resting metabolic rate in Metabolic disorder (E88.9: context) with structured follow-up of ALT & Fasting in Metabolic disorder (E88.9: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E88.9)).
- 2 Real-world patient consensus: Diagnostic registry E88.9: Metabolic disorder is managed within Weight & Metabolism.
- 3 Typical cash cost range: Differential triage of Metabolic disorder (E88.9) utilizes resting metabolic rate in Metabolic disorder (E88.9: context).
- 4 Top reported side effects / signs: Objective lab/clinical target for Metabolic disorder: HOMA-IR Insulin Resistance in Metabolic disorder (E88.9: Index) (< 1.4 (E88.9)) and ALT & Fasting in Metabolic disorder (E88.9: Triglycerides).
Ask our AI Specialists anything about Metabolic disorder
What Is Metabolic disorder?
Metabolic disorder—coded clinically as E88.9 across Weight & Metabolism guidelines—combines resting metabolic rate in Metabolic disorder (E88.9: context) with structured follow-up of ALT & Fasting in Metabolic disorder (E88.9: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E88.9)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Metabolic disorder (ICD-10 E88.9) is driven by adipocyte hypertrophy [Metabolic disorder E88.9]; specialists in Weight Management & Metabolic Syndrome monitor ALT & Fasting in Metabolic disorder (E88.9: Triglycerides) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Metabolic disorder (E88.9): central abdominal visceral in Metabolic disorder (E88.9: fat accumulation resistant)
- • Secondary Metabolic disorder clinical sign: persistent hunger signaling [Metabolic disorder E88.9]
- • Symptom flares in Metabolic disorder correlating with HOMA-IR Insulin Resistance in Metabolic disorder (E88.9: Index) deviation outside < 1.4 (E88.9)
- • Functional weight & metabolism impact requiring resting metabolic rate in Metabolic disorder (E88.9: context) evaluation (E88.9)
Metabolic disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Metabolic disorder (E88.9: Index) | < 1.4 (E88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Metabolic disorder (E88.9: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Metabolic disorder (E88.9: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Metabolic disorder
Treatment selection for Metabolic disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Metabolic disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of testosterone replacement therapy for treating metabolic disturbances: What a 1,373-Participant Study Found This study demonstrated greater improvement in metabolic profiles for patients given TRT versus placebo. International urology and nephrology • 2021-09-15 • Meta-Analysis | N = 1,373 | 99/100 | PMID 34089171 ↗ |
| New Insights on Tirzepatide reduces the predicted risk of atherosclerotic heart and blood vessel: What a 2,461-Participant Study Found Tirzepatide treatment significantly reduced the 10-year predicted risk of ASCVD versus placebo in patients with obesity or overweight without diabetes. Diabetes, obesity & metabolism • 2024-01-15 • Phase III Randomized Trial | N = 2,461 | 96/100 | PMID 37932236 ↗ |
| New Insights on Metabolic and heart and blood vessel effects of TX-001HR in menopausal women with: What a 1,835-Participant Study Found One episode of deep venous thrombosis and three cases of heart and blood vessel disease were observed, similar to expected rates of these events in the general population. Climacteric : the journal of the International Menopause Society • 2019-12-15 • Randomized Controlled Trial | N = 1,835 | 96/100 | PMID 31364889 ↗ |
| New Insights on Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated: What a 1,197-Participant Study Found In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The New England journal of medicine • 2025-06-05 • Phase III Randomized Trial | N = 1,197 | 96/100 | PMID 40305708 ↗ |
| New Insights on Positive Airway Pressure and Metabolic Markers in Children With Obstructive Sleep: What a 1,213-Participant Study Found Although evidence on effects of PAP on metabolic markers in children with OSA is encouraging, available literature is limited. Respiratory care • 2024-07-24 • Meta-Analysis | N = 1,213 | 94/100 | PMID 38653555 ↗ |
Metabolic disorder Patient Community & “People Like Me” Threads
Filter Metabolic disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.